The U.S. Cancer Biopsy market size was valued at US$ 7.56 billion in 2021 and is expected to hit US$ 18.58 billion by 2030, growing at a compound annual growth rate (CAGR) of 13.0% from 2022 to 2030.
The U.S. Cancer Biopsy market size was valued at US$ 7.56 billion in 2021 and is expected to hit US$ 18.58 billion by 2030, growing at a compound annual growth rate (CAGR) of 13.0% from 2022 to 2030.
Full Report is Ready | Request Sample of This Report@ https://www.novaoneadvisor.com/report/sample/6586
The increasing popularity of image-guided needle biopsies in precision medicine applications and a rise in the adoption of biopsies based on multi-parametric Magnetic Resonance (MR) imaging are the key factors driving the market. Furthermore, the advent of liquid biopsies, rising clinical implementation of biopsies, and advancements in quality and payment pertaining to genetic oncology diseases are expected to propel market growth in the near future. The increasing prevalence of oncology indications and the growing geriatric population is also likely to fuel the market growth. Combined development and the implementation of solid and liquid biopsies in oncology management are driving the market at a lucrative rate.
Report Scope of the U.S. Cancer Biopsy Market
| Report Coverage | Details |
| Market Size in 2021 | USD 7.56 Billion |
| Revenue Projection By 2030 | USD 18.58 Billion |
| Growth Rate | CAGR of 13.0% from 2022 to 2030 |
| Base Year | 2021 |
| Historical data | 2017 - 2020 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Type, application, site (organ) |
| Companies Mentioned | Becton, Dickinson and Company; IZI Medical Products; Johnson & Johnson; Argon Medical; Cook Medical; Spectra Medical Devices, Inc.; Medtronic plc.; Boston Scientific Corporation; Conmed Corporation; INRAD, Inc. |
The liquid biopsy industry is anticipated to witness exponential expansion in the near future wherein increasing strategic initiatives and investments by key entities involved in biopharmaceutical manufacturing and genomic data analysis are expected to play a central role. This field is rapidly growing, involving noninvasive tests for patients with or at risk of developing cancer. Liquid biopsies exhibit the potential to facilitate early tumor detection and evaluation of the efficacy of potential treatments in real-time.
The rapidly emerging field of precision medicine has enhanced the clinical implementation of novel oncology diagnostic tools. This field has expanded the use of these tools to obtain and analyze a large volume of genetic information related to oncology. Moreover, the development of advanced, next-generation sequencing tools has increased the utility of liquid biopsy tools in the detection of specific tumor-derived DNA (i.e., cfDNA).
Liquid biopsy tests are gaining increasing relevance to the everyday prescription of oncology therapeutics and clinical decisions, and laboratories are getting accredited as per the latest standards for molecular testing, which is expected to fuel the market growth in the coming years. An increase in the penetration of biopsies across the workflow of genetic cancer tests can be attributed to the robust reproducibility and reliability of the same.
Type Insights
The fine-needle aspiration biopsy (FNA) dominated the market in 2021 with a revenue share of more than 32.0%. This can be attributed to the fact that it is a simple and comparatively noninvasive approach that demands a skilled aspirator, coupled with the use of needles, stains, and syringes routinely. This has prompted several companies to invest in the development of FNAB systems.
Core needle procedures have gained significant traction over the past few years across breast biopsy applications. This shift from FNA to CNB is ongoing, especially among consumers in the U.S. The core needle biopsy, coupled with ultrasound guidance, has considerable potential to become the standard approach for amenable lesions. This is expected to promote the use of core needle biopsy in oncology indication diagnosis.
A surgical biopsy is a traditional approach for biopsies in patients suffering from cancer; in contrast to the needle biopsy. Incisional biopsies are most commonly adopted when needle biopsies fail to offer conclusive results, or the suspicious area is larger for sampling. This has contributed to the demand and revenue generated by surgical biopsies in oncology indication diagnosis.
Full Report is Ready |Quick Buy This Premium Report From Here@ https://www.novaoneadvisor.com/report/checkout/6586
Site (Organ) Insights
The breast segment accounted for the largest revenue share of 22.0% in 2021. The rising number of patients suspected to suffer from breast cancer has led to the increasing demand for a needle biopsy or surgical biopsy to obtain tissue for microscopic analysis. Image-guided needle biopsy has emerged as an accurate and safe nonsurgical approach for the detection of suspicious tissues in breast imaging.
Breast cancer surpassed the cases of lung cancer in women, becoming the leading cause of increasing cancer burden in 2020. Breast cancer in women represented more than 11% of all cancer cases. Thus, the rising burden of breast cancer is expected to supplement the market growth. Percutaneous image-guided needle biopsy is gaining demand in the effective management of abnormal breast lesions, further expected to contribute to the segment’s revenue.
Presently, biopsy has become a preferable approach to diagnose lung cancer. Various tools have been developed for lung tissue biopsy that is employed for the staging of lung cancer. Biopsy has emerged as a preferred choice of diagnostic tool attributed to its accuracy in lesion localization. In February 2021, Scripps Green Hospital used novel lung biopsy technology designed to improve lung cancer diagnosis.
Application Insights
The screening and monitoring application segment accounted for the largest revenue share of over 53.0% in 2021. Active participation of national research authorities has driven the adoption of different biopsy techniques in screening and monitoring applications. Several risk-stratification/decision-making algorithms are being developed to minimize side-effects associated with biopsies, in turn, expected to propel the segment growth.
The American Cancer Society (ACS) offers an annual report for healthcare professionals that summarizes present cancer screening guidelines, which are inclusive of present recommendations as well as updated recommendations. Biopsy has gained immense attention among professionals for early detection of cancer, particularly when it is difficult to make a direct screening recommendation.
Various biopsy techniques are commonly adopted in oncology indication diagnosis. Among these techniques, fine-needle aspiration has witnessed significant popularity in diagnostics that can be attributed to its minimally invasive nature and the ability to make a rapid diagnosis. Laparoscopic biopsy via abdominal incision is also gaining increasing attention in cancer diagnosis.
Key Companies & Market Share Insights
The U.S. market for cancer biopsy is expected to witness tremendous growth in the near future. The increasing number of technological collaborations between operating entities, coupled with the expanding product portfolio of operating players, has intensified the market competition.
The new product/ technology developments undertaken by key companies positively impact the market growth and increase their competitiveness in the market space. For instance, in June 2021, Grail has started the sale of its Galleri – a multi-cancer early detection blood test in the U.S. It is a liquid biopsy test for adult individuals with an increased risk of cancer. This strengthened its presence in this market space. Some prominent players in the U.S. cancer biopsy market include:
- Becton, Dickinson and Company
- IZI Medical Products
- Johnson & Johnson
- Argon Medical
- Cook Medical
- Spectra Medical Devices, Inc.
- Medtronic plc.
- Boston Scientific Corporation
- Conmed Corporation
- INRAD, Inc.
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at U.S. for the period of 2017 to 2030
- By Type
- Fine-needle Aspiration
- Pharma-use
- Clinical-use
- Core Biopsy
- Pharma-use
- Clinical-use
- Surgical Biopsy
- Pharma-use
- Clinical-use
- Skin Biopsy /Punch Biopsy
- Pharma-use
- Clinical-use
- Others
- Pharma-use
- Clinical-use
- Fine-needle Aspiration
- By Application
- Screening & Monitoring
- Diagnostics
- Investigational & Translational Research
- Pharma&Biopharma Discovery & Development
- By Site (Organ)
- Liver
- Breast
- Thyroid
- Prostate Gland
- Uterus & Cervix
- Kidney
- Bladder
- Lungs
- Pancreas
- Others
Click Here to View Full Report Table of Contents
Key Questions Answered in U.S. Cancer Biopsy Market Report
- What will be the sales/revenue generated by U.S. Cancer Biopsy across all regions during the forecast period?
- What are the opportunities in the U.S. Cancer Biopsy market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which application is expected to generate the highest revenue U.S. in 2030?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What is the market position of different companies operating in the U.S. market?
Full Report is Ready |Quick Buy This Premium Report From Here@ https://www.novaoneadvisor.com/report/checkout/6586
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333
About Us
Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.
We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. We endeavor to give our clients latest insights on upcoming technologies, new developing markets, dynamically changing business conditions and most recent business-driven applications. These insights help our clients to take informed decisions for their business growth.
For Latest Update Follow Us:
https://www.linkedin.com/company/nova-one-advisor